Oblique Therapeutics’ platform technology will be presented at the DDIP in Munich

Professor Owe Orwar, CEO of Oblique Therapeutics will make the first public disclosure of the company´s transformative platform for for functional antibody discovery and design at the 3rd Drug Discovery Innovation Programme 5-6 Oct 2017 Munich, Germany.